Skip to main content
Premium Trial:

Request an Annual Quote

Real Time Genomics Snares $5M Investment

NEW YORK (GenomeWeb News) – Real Time Genomics today announced a $5 million investment for the expansion of its commercial operations.

Steve Lombardi, CEO of Real Time Genomics, declined to identify who the investor is. The San Bruno, Calif.-based genomics analytics firm said that it comprises cash and the conversion of debt. The funding will be used for sales and marketing and for genomics applications development.

Steve Lombardi, CEO of Real Time Genomics, called the financing an "evolutionary milestone for the company where we begin to establish a strong commercial presence in the market."

The company introduced its platform in February. The first version called RTG Family Caller simultaneously analyzes genomic data from related individuals "within a patented Bayesian algorithmic framework" to identify all classes of variants. The system is designed to be compatible with sequencers from providers including Illumina, Life Technologies' Ion Torrent, and Roche's 454 Life Sciences.

In the past month, Real Time Genomics has forged deals with Knome, the J. Craig Venter Institute, and Omicia.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.